$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Introduction to the targeted genes and treatment principles of Bosutinib
2026-02-01 22:25:32
Check Details
Detailed explanation of the working principle and therapeutic mechanism of Upadacitinib
2026-02-01 22:25:32
Check Details
Nintedanib medical insurance reimbursement process and patient application guide
2026-02-01 22:25:32
Check Details
Binimetinib belongs to several generations of targeted drugs and an introduction to its pharmacological mechanism
2026-02-01 22:25:32
Check Details
Detailed explanation of the medical insurance negotiation results and reimbursement coverage of teclistamab
2026-02-01 22:25:32
Check Details
An introduction to the mechanism of action and therapeutic advantages of the FLT3 inhibitor Quizartinib
2026-02-01 22:25:32
Check Details
What are the common side effects of Tucatinib and can they be alleviated?
2026-02-01 22:25:32
Check Details
Is there an Indian generic version of Alpelisib available and is it cheaper?
2026-02-01 22:25:32
Check Details
What is the latest market price reference standard for Selumetinib in 2025?
2026-02-01 22:25:32
Check Details
What are the typical side effects that may occur when taking Cabozantinib?
2026-02-01 22:25:32
Check Details
What side effects may occur during bedaquiline treatment?
2026-02-01 22:25:32
Check Details
What are the most serious side effects of using domestically produced Dasatinib?
2026-02-01 22:25:32
Check Details
1
2
...
1811
1812
1813
1814
1815
1816
1817
...
10239
10240
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Ganaxolone Common Side Effects: Somnolence, Sedation and Safety Notes
2
Baxdrostat: Efficacy and Safety of a Novel Aldosterone Synthase Inhibitor
3
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
4
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
5
Anagrelide Cautions and Contraindications: Allergy, Hepatic, Cardiac and Bleeding Risks
6
FDA Accelerated Approval of Voceryq: First Plasmid DNA Immunotherapy for Adult Recurrent Respiratory Papillomatosis
7
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
8
Revumenib: Key Considerations Before and During Treatment
9
Pacritinib in Myelofibrosis: Evidence on Spleen Volume Reduction and Symptom Control
10
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
11
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
12
Pomalidomide vs Thalidomide: IMiD Generation Gap and MM Use